 <h1>Panitumumab Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to panitumumab: intravenous solution</i></p><h3>Warning</h3><p class="blackboxWarning-title">Intravenous route (Solution)</p><p>Dermatologic toxicities were reported in 90% of patients and were severe in 15% of patients receiving panitumumab monotherapy.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, panitumumab may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<i>Check with your doctor or nurse immediately</i> if any of the following side effects occur while taking panitumumab:</p><p>
<i>More common</i>
</p><ul>
<li>Anxiety</li>
<li>bloating or swelling of the face, arms, hands, lower legs, ankles, or feet</li>
<li>chest pain</li>
<li>chills</li>
<li>confusion</li>
<li>constipation</li>
<li>convulsions</li>
<li>cough</li>
<li>decreased urination</li>
<li>deep cracks, grooves, or lines in the skin</li>
<li>diarrhea</li>
<li>difficulty with swallowing</li>
<li>discoloration of the fingernails or toenails</li>
<li>drowsiness</li>
<li>dry mouth, lips, or skin</li>
<li>fainting</li>
<li>fast or irregular heartbeat</li>
<li>fever</li>
<li>flushing or redness of the skin</li>
<li>increased thirst</li>
<li>itching, pain, and swelling of the eyelid</li>
<li>itching, skin rash</li>
<li>loosening of the fingernails</li>
<li>loss of appetite</li>
<li>muscle pain or cramps</li>
<li>muscle spasms or twitching</li>
<li>nausea</li>
<li>rapid weight gain</li>
<li>rapid, shallow breathing</li>
<li>redness or soreness around the fingernails</li>
<li>sores, ulcers, or white spots on the lips, tongue, or inside the mouth</li>
<li>stomach pain</li>
<li>sunken eyes</li>
<li>swelling or inflammation of the mouth</li>
<li>tearing of the eyes</li>
<li>tingling of the hands or feet</li>
<li>trembling</li>
<li>troubled breathing</li>
<li>unusual tiredness or weakness</li>
<li>unusual weight gain or loss</li>
<li>unusually warm skin</li>
<li>vomiting</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Blurred vision</li>
<li>burning, dry, or itching eyes</li>
<li>discharge from the eyes or excessive tearing</li>
<li>dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position</li>
<li>facial swelling</li>
<li>headache</li>
<li>hives</li>
<li>noisy breathing</li>
<li>puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue</li>
<li>sweating</li>
<li>swelling of the eye, eyelid, or inner lining of the eyelid</li>
<li>tightness in the chest</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Chest discomfort</li>
<li>painful breathing</li>
<li>quick, shallow breathing</li>
<li>slight fever</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, or warmth at the injection site</li>
<li>large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs</li>
</ul><p>
<!-- end intravenous solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to panitumumab: intravenous solution</i></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Erythema (66%), pruritus (58%), acneiform dermatitis (57%), rash (22%), skin fissures (20%), exfoliative rash (18%), alopecia (15%)</p>
<p><b>Common</b> (1% to 10%): Dry skin, nail disorder, skin exfoliation, skin ulcer, pustular rash, popular rash, Palmar-plantar erythrodysesthesia syndrome</p>
<p><b>Postmarketing reports</b>: Skin necrosis, life threatening and fatal bullous mucocutaneous disease<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Abdominal pain (25%), nausea (23%), diarrhea (21%), constipation (21%), vomiting (19%)</p>
<p><b>Common</b> (1% to 10%): Stomatitis, mucosal inflammation, dry mouth<sup>[Ref]</sup></p><p>When used in combination with irinotecan, the incidence and severity of diarrhea is increased.  In a study of 19 patients who received panitumumab in combination with irinotecan, 5-fluorouracil, and leucovorin, the incidence of grade 3 or 4 diarrhea was 58% and was fatal in one patient.  The combination of panitumumab with leucovorin is not recommended.<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Anorexia (36%), hypomagnesemia (30%), hypokalemia (21%), weight loss (18%) </p>
<p><b>Common</b> (1% to 10%): Dehydration</p>
<p><b>Frequency not reported</b>: Hypocalcemia<sup>[Ref]</sup></p><p>Median magnesium levels decreased by 0.1 mmol/L.  Hypomagnesemia (grade 3 or 4) requiring oral or IV electrolyte repletion occurred in 2% of patients.  Hypomagnesemia occurred 6 weeks or longer after the initiation of panitumumab.  In some patients, hypomagnesemia was associated with hypocalcemia.  Patient's electrolytes should be monitored during and for eight weeks after the completion of panitumumab therapy.  Patients should be periodically monitored for hypomagnesemia and accompanying hypocalcemia during the eight weeks after the completion of panitumumab therapy.<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Dyspnea (18%), cough (15%)</p>
<p><b>Common</b> (1% to 10%): Epistaxis, pulmonary embolism</p>
<p><b>Uncommon</b> (0.1% to 1%): Pulmonary fibrosis</p>
<p><b>Frequency not reported</b>: Nasal dryness, interstitial lung disease (including fatal cases), lung infiltrates<sup>[Ref]</sup></p><p>Panitumumab should be permanently discontinued in patients developing interstitial lung disease, pneumonitis, or lung infiltrates.<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Growth of eyelashes, blepharitis, increased lacrimation, ocular hyperemia, dry eye, eye pruritus, eye irritation, conjunctivitis</p>
<p><b>Uncommon</b> (0.1% to 1%): eyelid irritation, keratitis</p>
<p><b>Rare</b> (less than 0.1%): Ulcerative keratitis<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p>Severe infusion reactions were identified as anaphylactic reaction, bronchospasm, fever, chills, and hypotension.  Although fatal infusion reactions have not been reported with panitumumab, fatalities have occurred with other monoclonal antibody products.  The infusion should be stopped if a severe infusion reaction occurs.  Depending on the severity and/or persistence of the reaction, panitumumab may need to be permanently discontinued.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Hypersensitivity</p>
<p><b>Rare</b> (less than 0.1%): Anaphylactic reaction, infusion reaction<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Anemia</p>
<p><b>Common</b> (1% to 10%): Leukopenia<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Paronychia (25%)</p>
<p><b>Common</b> (1% to 10%): Pustular rash, cellulitis, folliculitis, localized infection</p>
<p><b>Uncommon</b> (0.1% to 1%): Eye infection, eyelid infection</p>
<p><b>Postmarketing reports</b>: Angioedema<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Frequency not reported</b>: Headache<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue (26%), peripheral edema (12%)</p>
<p><b>Common</b> (1% to 10%): Mucosal inflammation, pyrexia, chills<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Frequency not reported</b>: Acute renal failure (in patients who developed diarrhea and dehydration)<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_2">2. Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp."   ([2006]):</p><p id="ref_3">3. "Product Information. Vectibix (panitumumab)." Amgen USA, Thousand Oaks, CA. </p><p id="ref_4">4. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p></div>
<div class="more-resources" id="moreResources">
<h2>More about panitumumab</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Espa√±ol</li>
<li>4 Reviews</li>
<li>Drug class: EGFR inhibitors</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Panitumumab Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Vectibix</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Colorectal Cancer</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to panitumumab: intravenous solution</i></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Erythema (66%), pruritus (58%), acneiform dermatitis (57%), rash (22%), skin fissures (20%), exfoliative rash (18%), alopecia (15%)</p><p><b>Common</b> (1% to 10%): Dry skin, nail disorder, skin exfoliation, skin ulcer, pustular rash, popular rash, Palmar-plantar erythrodysesthesia syndrome</p><p><b>Postmarketing reports</b>: Skin necrosis, life threatening and fatal bullous mucocutaneous disease<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Abdominal pain (25%), nausea (23%), diarrhea (21%), constipation (21%), vomiting (19%)</p><p><b>Common</b> (1% to 10%): Stomatitis, mucosal inflammation, dry mouth<sup>[Ref]</sup></p><p>When used in combination with irinotecan, the incidence and severity of diarrhea is increased.  In a study of 19 patients who received panitumumab in combination with irinotecan, 5-fluorouracil, and leucovorin, the incidence of grade 3 or 4 diarrhea was 58% and was fatal in one patient.  The combination of panitumumab with leucovorin is not recommended.<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Anorexia (36%), hypomagnesemia (30%), hypokalemia (21%), weight loss (18%) </p><p><b>Common</b> (1% to 10%): Dehydration</p><p><b>Frequency not reported</b>: Hypocalcemia<sup>[Ref]</sup></p><p>Median magnesium levels decreased by 0.1 mmol/L.  Hypomagnesemia (grade 3 or 4) requiring oral or IV electrolyte repletion occurred in 2% of patients.  Hypomagnesemia occurred 6 weeks or longer after the initiation of panitumumab.  In some patients, hypomagnesemia was associated with hypocalcemia.  Patient's electrolytes should be monitored during and for eight weeks after the completion of panitumumab therapy.  Patients should be periodically monitored for hypomagnesemia and accompanying hypocalcemia during the eight weeks after the completion of panitumumab therapy.<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Dyspnea (18%), cough (15%)</p><p><b>Common</b> (1% to 10%): Epistaxis, pulmonary embolism</p><p><b>Uncommon</b> (0.1% to 1%): Pulmonary fibrosis</p><p><b>Frequency not reported</b>: Nasal dryness, interstitial lung disease (including fatal cases), lung infiltrates<sup>[Ref]</sup></p><p>Panitumumab should be permanently discontinued in patients developing interstitial lung disease, pneumonitis, or lung infiltrates.<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Growth of eyelashes, blepharitis, increased lacrimation, ocular hyperemia, dry eye, eye pruritus, eye irritation, conjunctivitis</p><p><b>Uncommon</b> (0.1% to 1%): eyelid irritation, keratitis</p><p><b>Rare</b> (less than 0.1%): Ulcerative keratitis<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p>Severe infusion reactions were identified as anaphylactic reaction, bronchospasm, fever, chills, and hypotension.  Although fatal infusion reactions have not been reported with panitumumab, fatalities have occurred with other monoclonal antibody products.  The infusion should be stopped if a severe infusion reaction occurs.  Depending on the severity and/or persistence of the reaction, panitumumab may need to be permanently discontinued.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Hypersensitivity</p><p><b>Rare</b> (less than 0.1%): Anaphylactic reaction, infusion reaction<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Anemia</p><p><b>Common</b> (1% to 10%): Leukopenia<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Paronychia (25%)</p><p><b>Common</b> (1% to 10%): Pustular rash, cellulitis, folliculitis, localized infection</p><p><b>Uncommon</b> (0.1% to 1%): Eye infection, eyelid infection</p><p><b>Postmarketing reports</b>: Angioedema<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Frequency not reported</b>: Headache<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue (26%), peripheral edema (12%)</p><p><b>Common</b> (1% to 10%): Mucosal inflammation, pyrexia, chills<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Frequency not reported</b>: Acute renal failure (in patients who developed diarrhea and dehydration)<sup>[Ref]</sup></p><p id="ref_1">1. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_2">2. Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp."   ([2006]):</p><p id="ref_3">3. "Product Information. Vectibix (panitumumab)." Amgen USA, Thousand Oaks, CA. </p><p id="ref_4">4. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><h2>More about panitumumab</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Espa√±ol</li>
<li>4 Reviews</li>
<li>Drug class: EGFR inhibitors</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Panitumumab Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Colorectal Cancer</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>